Office of the Director, National Institutes of Health; Notice of Meeting, 72453 [05-23590]
Download as PDF
<![CDATA[
Federal Register / Vol. 70, No. 232 / Monday, December 5, 2005 / Notices
carcinoma. The present technology
relates to the isolation and
characterization of a novel neutralizing
chimpanzee monoclonal antibody to
HBV. The antibody was identified
through a combinatorial antibody
library constructed from bone marrow
cells of a chimpanzee experimentally
infected with HBV. The selected
monoclonal antibody has been shown to
react equally well with wild-type HBV
and the most common neutralization
escape mutant variants. Therefore, this
monoclonal antibody with high affinity
and broad reactivity may have distinct
advantages over other approaches to
immunoprophylaxis and
immunotherapy of chronic HBV
infection, as most of the monoclonal
antibodies currently in use are not
sufficiently and broadly reactive to
prevent the emergence of neutralization
escape mutants of HBV. This technology
describes such antibodies, fragments of
such antibodies retaining hepatitis B
virus-binding ability, fully human or
humanized antibodies retaining
hepatitis B virus-binding ability, and
pharmaceutical compositions including
such antibodies. This invention further
describes isolated nucleic acids
encoding the antibodies and host cells
transformed with nucleic acids. In
addition, this invention provides
methods of employing these antibodies
and nucleic acids in the in vitro and in
vivo diagnosis, prevention and therapy
of HBV diseases.
In addition to licensing, the
technology is available for further
development through collaborative
research opportunities with the
inventors.
Polypeptide Multimers Having
Antiviral Activity
Carol Weiss et al. (FDA)
PCT Application No. PCT/US03/25295
filed 14 Aug 2003, which published
as WO 2005/018666 on 03 Mar 2005
(HHS Reference No. E–155–2003/0PCT–01)
Licensing Contact: Susan Ano; 301/435–
5515; anos@mail.nih.gov.
The technology describes polypeptide
multimers that have antiviral and
immunogenic activity against HIV.
These multimers consist of at least one
monomer of the highly conserved N and
C heptad regions of gp41 in a ratio of at
least 2:1 N to C heptad, with the N and
C heptads being connected by linkers.
The monomer forms homodimers and
homotrimers in solution and mimic
fusion intermediate structure. Further,
the technology also describes a method
of raising a broadly neutralizing
antibody response to HIV by
administering the polypeptide
VerDate Aug<31>2005
17:14 Dec 02, 2005
Jkt 208001
multimers mentioned above. Thus,
these polypeptide multimers may be
used as antiviral (anti-HIV) agents.
Because the structure of these
polypeptide multimers mimics the gp41
fusion intermediate, they can also be
used to identify compounds that may
inhibit the fusion process.
In addition to licensing, the
technology is available for further
development through collaborative
research opportunities with the
inventors.
Dated: November 15, 2005.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E5–6803 Filed 12–2–05; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director, National
Institutes of Health; Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the meeting of the
Advisory Committee to the Director,
National Institutes of Health (NIH).
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
A portion of the meeting will be
closed to the public in accordance with
the provisions set forth in sections
552b(c)(6) and 552b(c)(9)(B), Title 5
U.S.C., as amended, because the
disclosure of which would constitute a
clearly unwarranted invasion of
personal privacy and the premature
disclosure of information and the
discussions would likely to significantly
frustrate implementation of the
program.
Name of Committee: Advisory Committee
to the Director, NIH.
Date: December 1–2, 2005.
Closed: December 1, 2005, 8:30 a.m. to 9:45
a.m.
Agenda: Office of Portfolio Analysis and
Strategic Initiatives (OPASI).
Place: National Institutes of Health, 9000
Rockville Pike, Building 31, Conference
Room 6, Bethesda, MD 20892.
Open: December 1, 2005, 10 a.m. to 4:30
p.m.
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
72453
Agenda: Among the topics proposed for
discussion are: (1) NIH Director’s Report; (2)
Clinical and Translational Science Awards;
(3) NIH Director’s Council of Public
Representatives Liaison Report; and (4)
update on NIH Neurosciences Blueprint.
Place: National Institutes of Health, 9000
Rockville Pike, Building 31, Conference
Room 6, Bethesda, MD 20892.
Open: December 2, 2005, 9 a.m. to 12 p.m.
Agenda: Among the topics proposed for
discussion are: (1) Office of Portfolio
Analysis and Strategic Initiatives (OPASI); (2)
Public Access Update; and (3) Workgroup
Report on Outside Awards for NIH
Employees.
Place: National Institutes of Health, 9000
Rockville Pike, Building 31, Conference
Room 6, Bethesda, MD 20892.
Contact Person: Shelly Pollard, ACD
Coordinator, Office of Communications and
Public Liaison, Office of the Director,
National Institutes of Health, 31 Center Drive,
Building 31, Room 5B64, Bethesda, MD
20892, Phone: (301) 496–0959,
pollards@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
into the building by non-government
employees. Persons without a government
I.D. will need to show a photo I.D. and signin at the security desk upon entering the
building.
Information is also available on the
Institute’s/Center’s home page: https://
www.nih.gov/about/director/acd.htm where
an agenda and any additional information for
the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.14, Intramural Research
Training Award; 93.22, Clinical Research
Loan Repayment Program for Individuals
from Disadvantaged Backgrounds; 93.232,
Loan Repayment Program for Research
Generally; 93.39, Academic Research
Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan
Repayment Program; 93.187, Undergraduate
Scholarship Program for Individuals from
Disadvantaged Backgrounds, National
Institutes of Health, HHS)
Dated: November 22, 2005.
Nancy Middendorf,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–23590 Filed 12–2–05; 8:45 am]
BILLING CODE 4140–01–M
E:\FR\FM\05DEN1.SGM
05DEN1
]]>Agencies
[Federal Register Volume 70, Number 232 (Monday, December 5, 2005)]
[Notices]
[Page 72453]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-23590]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Office of the Director, National Institutes of Health; Notice of
Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of the meeting of
the Advisory Committee to the Director, National Institutes of Health
(NIH).
The meeting will be open to the public as indicated below, with
attendance limited to space available. Individuals who plan to attend
and need special assistance, such as sign language interpretation or
other reasonable accommodations, should notify the Contact Person
listed below in advance of the meeting.
A portion of the meeting will be closed to the public in accordance
with the provisions set forth in sections 552b(c)(6) and 552b(c)(9)(B),
Title 5 U.S.C., as amended, because the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy and the
premature disclosure of information and the discussions would likely to
significantly frustrate implementation of the program.
Name of Committee: Advisory Committee to the Director, NIH.
Date: December 1-2, 2005.
Closed: December 1, 2005, 8:30 a.m. to 9:45 a.m.
Agenda: Office of Portfolio Analysis and Strategic Initiatives
(OPASI).
Place: National Institutes of Health, 9000 Rockville Pike,
Building 31, Conference Room 6, Bethesda, MD 20892.
Open: December 1, 2005, 10 a.m. to 4:30 p.m.
Agenda: Among the topics proposed for discussion are: (1) NIH
Director's Report; (2) Clinical and Translational Science Awards;
(3) NIH Director's Council of Public Representatives Liaison Report;
and (4) update on NIH Neurosciences Blueprint.
Place: National Institutes of Health, 9000 Rockville Pike,
Building 31, Conference Room 6, Bethesda, MD 20892.
Open: December 2, 2005, 9 a.m. to 12 p.m.
Agenda: Among the topics proposed for discussion are: (1) Office
of Portfolio Analysis and Strategic Initiatives (OPASI); (2) Public
Access Update; and (3) Workgroup Report on Outside Awards for NIH
Employees.
Place: National Institutes of Health, 9000 Rockville Pike,
Building 31, Conference Room 6, Bethesda, MD 20892.
Contact Person: Shelly Pollard, ACD Coordinator, Office of
Communications and Public Liaison, Office of the Director, National
Institutes of Health, 31 Center Drive, Building 31, Room 5B64,
Bethesda, MD 20892, Phone: (301) 496-0959, pollards@mail.nih.gov.
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has instituted stringent
procedures for entrance into the building by non-government
employees. Persons without a government I.D. will need to show a
photo I.D. and sign-in at the security desk upon entering the
building.
Information is also available on the Institute's/Center's home
page: https://www.nih.gov/about/director/acd.htm where an agenda and
any additional information for the meeting will be posted when
available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.14,
Intramural Research Training Award; 93.22, Clinical Research Loan
Repayment Program for Individuals from Disadvantaged Backgrounds;
93.232, Loan Repayment Program for Research Generally; 93.39,
Academic Research Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan Repayment Program; 93.187,
Undergraduate Scholarship Program for Individuals from Disadvantaged
Backgrounds, National Institutes of Health, HHS)
Dated: November 22, 2005.
Nancy Middendorf,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 05-23590 Filed 12-2-05; 8:45 am]
BILLING CODE 4140-01-M
